IntelliPharmaCeutics International’s (I) “Buy” Rating Reaffirmed at HC Wainwright

IntelliPharmaCeutics International (TSE:I) (NASDAQ:IPCI)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Friday.

Shares of IntelliPharmaCeutics International (TSE I) opened at C$3.23 on Friday. The company has a market cap of $41.24, a price-to-earnings ratio of -7.51 and a beta of 0.61. IntelliPharmaCeutics International has a 52-week low of C$1.78 and a 52-week high of C$4.50.

ILLEGAL ACTIVITY NOTICE: “IntelliPharmaCeutics International’s (I) “Buy” Rating Reaffirmed at HC Wainwright” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/24/intellipharmaceutics-internationals-i-buy-rating-reaffirmed-at-hc-wainwright.html.

About IntelliPharmaCeutics International

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Ratings for IntelliPharmaCeutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply